cadranel jacques retweeted
📢IFCT-2502 LIMPID : les 3 premiers patients inclus à Metz Schuman, AP-HP Bobigny et AP-HM Marseille
🎯Améliorer la prise en charge des patients avec un cancer bronchique associé à une pneumopathie interstitielle diffuse (PID).
🔎ifct.fr/etudes-cliniqu…
@BDuchemann @CadranelJ
🎯Améliorer la prise en charge des patients avec un cancer bronchique associé à une pneumopathie interstitielle diffuse (PID).
🔎ifct.fr/etudes-cliniqu…
@BDuchemann @CadranelJ
0
1
1
103
cadranel jacques retweeted
Presented at #ESMO26:
In patients with previously treated advanced non–small-cell lung cancer with a 𝘒𝘙𝘈𝘚 G12C mutation, median progression-free survival was 9.8 months with the KRAS G12C inhibitor divarasib and 5.7 months with sotorasib or adagrasib. Full phase 3 Krascendo //t.co/A4dduLqRn1
@myESMO
In patients with previously treated advanced non–small-cell lung cancer with a 𝘒𝘙𝘈𝘚 G12C mutation, median progression-free survival was 9.8 months with the KRAS G12C inhibitor divarasib and 5.7 months with sotorasib or adagrasib. Full phase 3 Krascendo //t.co/A4dduLqRn1
@myESMO
2
53
140
17,514
cadranel jacques retweeted
Presented at #ESMO26:
In patients with 𝘌𝘎𝘍𝘙-mutated and MET-altered non–small-cell lung cancer that had progressed during osimertinib therapy, osimertinib plus savolitinib (a MET tyrosine kinase inhibitor) led to longer survival than platinum–pemetrexed. Full phase 3 SAFFRON t.co/cGGRus8pjE
@myESMO
In patients with 𝘌𝘎𝘍𝘙-mutated and MET-altered non–small-cell lung cancer that had progressed during osimertinib therapy, osimertinib plus savolitinib (a MET tyrosine kinase inhibitor) led to longer survival than platinum–pemetrexed. Full phase 3 SAFFRON t.co/cGGRus8pjE
@myESMO
1
37
131
20,760
cadranel jacques retweeted
#ESMO26 Dr. Yilong Wu @ThomasW35874311 presents SANOVO: 1L osimertinib + savolitinib/placebo in EGFR+ NSCLC with MET overexpression. Wow. PFS 24.8 vs 11.1m, HR 0.45 with OS 44.5 vs 34.9m, HR 0.48. RR 81% vs 68%. Toxicities below. Very impressive. #ESMOAmbassadors
1
21
52
2,472
cadranel jacques retweeted
@IFCTlung @ToffartC A great presentation by Prof. Anne-Claire Toffart (Grenoble University Hospital), on behalf of the French Intergroup IFCT.
A very encouraging message, since longer is not systematically better! Accrual is continuing : Join the French investigator centers already engaged 🫁
A very encouraging message, since longer is not systematically better! Accrual is continuing : Join the French investigator centers already engaged 🫁
0
4
5
166
cadranel jacques retweeted
#ESMO26 Dr. Jarushka Naidoo @DrJNaidoo with a fantastic discussion on de-escalation trials in oncology. A call out on why de-escalation studies are important and their limitations. And for MOIO in particular - lessons on trial design, non-inferiority, and pragmatism. A lved in trial design. #ESMOAmbassadors
2
23
52
4,164
cadranel jacques retweeted
#ESMO26 Dr. @ToffartC with phase II IFCT-2103 DIAL trial. After 6m chemo-pembro, pts w/o progression randomized to complete 2y of therapy or stop IO (cont maintpemetrexed). Similar 18m & 24m survival & less toxicity with shorter IO course. Phase III ongoing #ESMOAmbassadors
0
10
15
1,148
Just online. Very happy to participate to this important paper for young women with pregnancy and oncogen driven advanced NSLCC. Help us to better manage this condition. @NarjustFlorezMD and #MImbimbo 🙏
1
0
1
113
cadranel jacques retweeted
🔥 Exciting update on our encorafenib + binimetinib efficacy data from the @IFCTlung ONCOBRAF Phase II trial in 1L & 2L BRAF V600E-mut NSCLC! Now a new therapeutic standard in many countries for our BRAF pts (vs. dabrafenib + trametinib). A must-see poster at #ESMO26 @C_Ricordel
📅 23–27 October | IFCT at #ESMO26 in Madrid
👇 Check out the details of our presentations! @myESMO @IFCTlung #cancer #research #NSCLC
0
6
13
893
cadranel jacques retweeted
WCLC 2026 | What am I watching? 🫁
Three spaces. 15 readouts worth watching.
🔹 Early NSCLC — Can we push more patients toward cure?
🔹 Advanced NSCLC — HER2, EGFR, ROS1 and ADC + IO reshape the first-line space.
🔹 SCLC — PCI, B7-H3 ADCs and DLL3: several long-standing nswers.
Some studies may reinforce practice.
Some may challenge it.
And some have already surprised us.
Seoul | 12–15 September 2026
Saving WCLC 2026 watchlist here 👇
#MVOnco #WCLC26 #IASLC #LungCancer #NSCLC #SCLC #ThoracicOncology #MedicalOncology
Three spaces. 15 readouts worth watching.
🔹 Early NSCLC — Can we push more patients toward cure?
🔹 Advanced NSCLC — HER2, EGFR, ROS1 and ADC + IO reshape the first-line space.
🔹 SCLC — PCI, B7-H3 ADCs and DLL3: several long-standing nswers.
Some studies may reinforce practice.
Some may challenge it.
And some have already surprised us.
Seoul | 12–15 September 2026
Saving WCLC 2026 watchlist here 👇
#MVOnco #WCLC26 #IASLC #LungCancer #NSCLC #SCLC #ThoracicOncology #MedicalOncology
0
14
51
3,149
cadranel jacques retweeted
Landmark, practice changing study at #WCLC26. The phase III MAVERICK study shows no improvement in OS with PCI for SCLC, across limited and extensive stages, with worse cognitive failure free survival and increased toxicity in PCI arm.
The end of the PCI era.
The end of the PCI era.
3
91
194
14,766
cadranel jacques retweeted
We now have TWO studies showing B7-H3 ADCs vastly superior to standard topotecan for relapsed SCLC: tam-peli and ris-rez. These studies were different - different agents, different baseline demographics of pts, etc - but the outcomes were similar, control arms performed reinforce each other. Looking forward to global studies and to first-line studies. The ADC era soundly here for SCLC and these will replace chemotherapy across lines, in my opinion. #WCLC26
3
39
121
11,624
cadranel jacques retweeted
Presented at #WCLC26:
Among patients with relapsed small-cell lung cancer after chemotherapy, treatment with tambotatug pelitecan led to longer survival than treatment with topotecan, with fewer adverse events of grade 3 or higher. Full phase 3 TAISHAN-302 trial results: nej.md/4xKtvcF
@IASLC
Among patients with relapsed small-cell lung cancer after chemotherapy, treatment with tambotatug pelitecan led to longer survival than treatment with topotecan, with fewer adverse events of grade 3 or higher. Full phase 3 TAISHAN-302 trial results: nej.md/4xKtvcF
@IASLC
4
53
140
48,155
cadranel jacques retweeted
IASLC expert panel proposes an updated pulmonary carcinoid/NET classification ( Expected to be included into the forthcoming WHO thoracic blue book)
1. Keep “carcinoid” as the main diagnostic term for thoracic clinicians, while moving toward the “NET” nomenclature used in other a diagnostic criterion. 5% threshold is pulmonary specific
3. Formally recognize rare carcinoid/NET G3 tumors (higher proliferation, but molecularly closer to NETs than to high-grade NECs)
More on jto.org/article/S1556-…
Slides below from Dr. Bellizzi’s presentation: What’s New in Neuroendocrine Tumors (WHO 6th Edition, 2026)
youtube.com/live/o8IqIDiN_… #pathology #pathX
1. Keep “carcinoid” as the main diagnostic term for thoracic clinicians, while moving toward the “NET” nomenclature used in other a diagnostic criterion. 5% threshold is pulmonary specific
3. Formally recognize rare carcinoid/NET G3 tumors (higher proliferation, but molecularly closer to NETs than to high-grade NECs)
More on jto.org/article/S1556-…
Slides below from Dr. Bellizzi’s presentation: What’s New in Neuroendocrine Tumors (WHO 6th Edition, 2026)
youtube.com/live/o8IqIDiN_… #pathology #pathX
1
47
117
6,415
cadranel jacques retweeted
Pulmonary Nodules: an excellent review!
🫁🩻🚬🎞⏳️🐍⚖️⚔️🎯
doi.org/10.1056/NEJMcp…
@NEJM @pneumosbpt @ALATorax @NeumoMadrid @Neumosur @SeparRespira @SOCAP @ers @ats
🫁🩻🚬🎞⏳️🐍⚖️⚔️🎯
doi.org/10.1056/NEJMcp…
@NEJM @pneumosbpt @ALATorax @NeumoMadrid @Neumosur @SeparRespira @SOCAP @ers @ats
0
76
196
9,830
cadranel jacques retweeted
Is anyone less than impressed w/ #HARMONi ?
▫️PFS at 6.8 mo is less than basic COMPEL trial of chemo + TKI of 8.4 mo.
▫️Looks much like a VEGF curve from the 2000's, not an IO curve.
▫️It requires stopping TKI.
For pts w/ prior brain mets, this approach warrants a lot of caution.
▫️PFS at 6.8 mo is less than basic COMPEL trial of chemo + TKI of 8.4 mo.
▫️Looks much like a VEGF curve from the 2000's, not an IO curve.
▫️It requires stopping TKI.
For pts w/ prior brain mets, this approach warrants a lot of caution.
3
7
38
4,988
cadranel jacques retweeted
🆙 #WCLC26 #LCSM Mini Oral Session
🔥 SOHO-01: Molecular Landscape of Acquired Resistance to Sevabertinib in HER2-mutant NSCLC
🎯85 pts with paired BL-PD plasma NGS
🎯Resistance-associated events in 30.1%
🎯Secondary HER2 T862A 16.4%, HER2 amplification 2.7%; C805S not detected
rations less frequent (PIK3CA/PTEN, MAPK pathway, 12.3%)
🎙️ @LeXiuning
🔢 MO12.04
☑️ NCT05099172
🔗 cattendee.abstractsonline.com/meeting/21487/…
@OncoAlert @Larvol @IASLC
🔥 SOHO-01: Molecular Landscape of Acquired Resistance to Sevabertinib in HER2-mutant NSCLC
🎯85 pts with paired BL-PD plasma NGS
🎯Resistance-associated events in 30.1%
🎯Secondary HER2 T862A 16.4%, HER2 amplification 2.7%; C805S not detected
rations less frequent (PIK3CA/PTEN, MAPK pathway, 12.3%)
🎙️ @LeXiuning
🔢 MO12.04
☑️ NCT05099172
🔗 cattendee.abstractsonline.com/meeting/21487/…
@OncoAlert @Larvol @IASLC
🔥 #ESMO25 🇩🇪
🔥 #LCSM Proffered paper, mets
☑️SOHO-01: Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer
☑️mPFS (PreTx w/o HER2, Pre HER2-ADC, Tx-naive): 8.3m, 5.5m, and not reached
🎙️ @LeXiuning
@OncoAlert @myESMO @Larvol
0
8
16
5,558
cadranel jacques retweeted
Is lack of OS surprising?
▫️PD-L1 always had slightly weaker ORR compared to PD-1, across cancers.
▫️Exceptions are settings when tolerability is more important than potency (eg w/ XRT, SCLC, etc).
▫️PD-L1 always had slightly weaker ORR compared to PD-1, across cancers.
▫️Exceptions are settings when tolerability is more important than potency (eg w/ XRT, SCLC, etc).
🔥AEGEAN update in @JCO_ASCO, Perioperative durvalumab + neoadjuvant chemo in resectable #NSCLC
➡️EFS HR 0.69 (0.55-0.88) at 25.9 mo
➡️OS HR 0.89 (0.70-1.14)
➡️Benefit for pCR and patients receiving adjuvant treatment, though
🧐Same question as three years ago: is the thing, both in pCR and in unselected non-pCR patients?
Link 👇
#LCSM
1
4
15
2,657